Status:
COMPLETED
Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropathy
Lead Sponsor:
Nanjing University School of Medicine
Conditions:
IGA Nephropathy
Eligibility:
All Genders
12-65 years
Phase:
NA
Brief Summary
A single-center random parallel study to compare the efficacy and safety of Mycophenolate mofetil versus intravenous Cyclophosphamide pulses in the treatment of crescentic IgA nephropathy
Detailed Description
IgA nephropathy is an immune-complex glomerulopathy that can result in capillary necrosis or extracapillary proliferation (crescents). Several studies have documented a higher incidence of hypertensio...
Eligibility Criteria
Inclusion
- Patient with a diagnosis of IgAN without deposition of C4 and C1q, age 10-70y, sex free
- Gross hematuria or an active urine sediment
- Segmental necrotizing lesion of the capillary wall
- Cellular or fibrocellular crescents ≥ 10%
- Fibrinoid degeneration of small vessels
- Fibrin positive Three or more items, with provision of criteria informed consent
Exclusion
- More than four-week treatment with cytotoxic drug, such as CTX, CsA and MMF, prior to enrollment
- Immune deficiency
- Serum creatinine ≥ 5.0mg/dl
- Previous malignancy
- Pregnancy
- Hepatitis
- Diabetic mellitus or obesity
- Severe infection or CVS complications
- Henoch-Schonlein purpura nephritis, systemic vasculitis, SLE
Key Trial Info
Start Date :
January 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2006
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00301600
Start Date
January 1 2003
End Date
January 1 2006
Last Update
May 27 2010
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine
Nanjing, Jiangsu, China, 210002